AstraZeneca’s decision not to engage in possible merger discussions with pharmaceutical rival Pfizer even after an offer upped to $119 billion has caused a riff between AstraZeneca shareholders, reports say.
Significant shareholders of the UK pharmaceutical firm have voiced both their opposition and support for such a merger Wednesday after AstraZeneca …read more
Source: Global Competition Law Blogs